Eventide Asset Management’s Sutro Biopharma STRO Stock Holding History

Eventide Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.4M	Sell	585,262 -130,045	-18%	-$4.05M	0.26%	113
2026 Q1	$17.8M	Buy	+715,307	New	+$12.9M	0.29%	112
2022 Q4	–	Sell	-270,898	Closed	-$15M	–	155
2022 Q3	$15M	Hold	270,898	–	–	0.3%	85
2022 Q2	$14.1M	Hold	270,898	–	–	0.3%	85
2022 Q1	$22.3M	Hold	270,898	–	–	0.35%	81
2021 Q4	$40.3M	Buy	270,898 +33,800	+14%	+$6.06M	0.52%	67
2021 Q3	$44.8M	Hold	237,098	–	–	0.59%	56
2021 Q2	$44.1M	Hold	237,098	–	–	0.59%	55
2021 Q1	$54M	Hold	237,098	–	–	0.8%	45
2020 Q4	$51.5M	Buy	237,098 +38,500	+19%	+$6.37M	0.79%	42
2020 Q3	$20M	Hold	198,598	–	–	0.39%	75
2020 Q2	$15.4M	Buy	198,598 +70,000	+54%	+$6.72M	0.34%	78
2020 Q1	$13.1M	Buy	128,598 +4,108	+3%	+$432K	0.42%	70
2019 Q4	$13.7M	Buy	124,490 +71,990	+137%	+$7.42M	0.39%	70
2019 Q3	$4.77M	Sell	52,500 -71,990	-58%	-$7.27M	0.16%	85
2019 Q2	$13.8M	Hold	124,490	–	–	0.42%	73
2019 Q1	$13.8M	Hold	124,490	–	–	0.47%	67
2018 Q4	$10.9M	Hold	124,490	–	–	0.48%	65
2018 Q3	$18.1M	Buy	+124,490	New	+$18.8M	0.67%	54

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Eventide Asset Management's STRO Position: Q2 2026 in Review

Eventide Asset Management reduced its Sutro Biopharma (STRO) stake by 18% in Q2 2026, selling an estimated $4.05M and leaving 585,262 shares worth $19.4M. The position accounts for 0.26% of the portfolio, ranked #113.

Eventide Asset Management first reported a position in STRO in Q3 2018 and has held it in 19 quarters since. The position peaked at $54M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Eventide Asset Management held 585,262 shares of Sutro Biopharma worth $19.4M as of Q2 2026.
Eventide Asset Management sold 130,045 Sutro Biopharma shares in Q2 2026, an estimated $4.05M.
Sutro Biopharma made up 0.26% of Eventide Asset Management's portfolio in Q2 2026, its #113 holding.
Eventide Asset Management first reported a position in Sutro Biopharma in Q3 2018 and has held it in 19 quarters since.
Eventide Asset Management's Sutro Biopharma position peaked at $54M in Q1 2021.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.